Study explores potential mechanisms behind decline in vascular events with empagliflozin


eMediNexus    03 February 2018

Data from a post-hoc analysis of the landmark EMPA-REG OUTCOME study show that changes in markers of plasma volume were the main factors causing a 38% decline in the risk of death due to vascular events with empagliflozin in patients with type 2 diabetes and established cardiovascular disease. These findings are published in the February 2018 issue of Diabetes Care.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.